IMTX

Immatics NV (IMTX)

Immatics NV

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:IMTX

1 2 3 4 5 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/14	20 : 00	GlobeNewswire Inc.	Immatics Announces First Quarter 2024 Financial Results and Business Update	NASDAQ:IMTX	Immatics NV
2024/03/21	20 : 00	GlobeNewswire Inc.	Immatics Announces Full Year 2023 Financial Results and Corporate Update	NASDAQ:IMTX	Immatics NV
2024/01/23	02 : 52	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMTX	Immatics NV
2024/01/19	22 : 58	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:IMTX	Immatics NV
2024/01/18	10 : 30	GlobeNewswire Inc.	Immatics Announces Pricing of $175 Million Public Offering	NASDAQ:IMTX	Immatics NV
2024/01/18	06 : 11	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:IMTX	Immatics NV
2024/01/18	06 : 01	GlobeNewswire Inc.	Immatics Announces Proposed Public Offering	NASDAQ:IMTX	Immatics NV
2024/01/16	18 : 06	PR Newswire (US)	DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing	NASDAQ:IMTX	Immatics NV
2024/01/16	17 : 59	PR Newswire (US)	DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing	NASDAQ:IMTX	Immatics NV
2023/11/30	18 : 00	GlobeNewswire Inc.	Levicept Appoints Eliot Forster as CEO	NASDAQ:IMTX	Immatics NV
2023/11/14	21 : 00	GlobeNewswire Inc.	Immatics Announces Third Quarter 2023 Financial Results and Business Update	NASDAQ:IMTX	Immatics NV
2023/11/08	21 : 30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMTX	Immatics NV
2023/11/08	21 : 00	GlobeNewswire Inc.	Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial	NASDAQ:IMTX	Immatics NV
2023/10/24	20 : 10	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMTX	Immatics NV
2023/10/24	20 : 00	GlobeNewswire Inc.	Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy	NASDAQ:IMTX	Immatics NV
2023/09/14	13 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:IMTX	Immatics NV
2023/09/14	06 : 03	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:IMTX	Immatics NV
2023/09/11	20 : 00	GlobeNewswire Inc.	Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics	NASDAQ:IMTX	Immatics NV
2023/09/11	19 : 33	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMTX	Immatics NV
2023/08/26	05 : 11	Edgar (US Regulatory)	Form F-3 - Registration statement by foreign private issuers	NASDAQ:IMTX	Immatics NV
2023/08/17	20 : 05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMTX	Immatics NV
2023/08/17	20 : 00	GlobeNewswire Inc.	Immatics Announces Second Quarter 2023 Financial Results and Business Update	NASDAQ:IMTX	Immatics NV
2023/08/10	20 : 08	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMTX	Immatics NV
2023/08/10	20 : 00	GlobeNewswire Inc.	Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors	NASDAQ:IMTX	Immatics NV
2023/07/24	20 : 15	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMTX	Immatics NV
2023/07/24	20 : 00	GlobeNewswire Inc.	Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb	NASDAQ:IMTX	Immatics NV
2023/06/21	05 : 21	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:IMTX	Immatics NV
2023/05/16	20 : 06	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:IMTX	Immatics NV
2023/05/16	20 : 00	GlobeNewswire Inc.	Immatics Announces First Quarter 2023 Financial Results and Business Update	NASDAQ:IMTX	Immatics NV
2023/05/02	20 : 00	GlobeNewswire Inc.	Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME	NASDAQ:IMTX	Immatics NV